# Femtobiomed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/femtobiomed

- Industry: Biotechnology
- Headquarters: Gyeonggi-do, South Korea
- Website: www.femtobiomed.com
- Total disclosed funding: $8M
- Latest round: Series B (Feb 14, 2019)
- Investors on record: 4

## About

Femtobiomed Inc. is a biotechnology company specializing in innovative cell therapy solutions through advanced nonviral therapeutics and multiplexed engineering technologies, aimed at enhancing cell production yield and viability. Founded in 2011 and headquartered in Seongnam, South Korea, Femtobiomed Inc. delivers pioneering solutions in cell therapy and has undergone strategic advancements in its operations. In April 2024, Korea Investment Partners acquired 362,625 shares in Femtobiomed Inc. at KRW 8,273 apiece for KRW 2.9 billion, in a PIPE transaction.. The company was founded by Sanghyun Lee, who has a history of entrepreneurial ventures in the biotechnology field. Femtobiomed specializes in innovative solutions for cell therapy, primarily focusing on advanced nonviral cell therapeutics and multiplexed cell engineering technologies. Its core products include the Decentralized Cell Therapy Manufacturing Device and the Electroporator, which utilize partitioned flow technology for simplified electroporation and bufferless transfection. This technology addresses significant challenges in the conventional viral cell and gene therapy (CAGT) sector by enhancing production yield and maintaining high cell viability in a cost-effective manner. FEMTOBIOMED targets a diverse client base, including researchers and clinicians within the biotechnology and pharmaceutical industries, primarily serving markets in North America, Europe, and select regions in Asia. Femtobiomed operates on a transactional model that primarily involves B2B interactions with researchers, healthcare institutions, and biotech companies. The firm's revenue for the most recent year in 2024 was KRW 116,665.7 million, while the EBITDA for the same period was KRW -3,513,279.8 million. Clients engage in direct purchases of the Decentralized Cell Therapy Manufacturing Device and the Electroporator, alongside necessary consumable supplies. Pricing structures reflect the complexity and innovative nature of their offerings, fostering long-term collaborations and continual revenue generation. Femtobiomed plans to expand its product offerings with upcoming innovations in cell therapy technology, targeting a launch in the next 18 months. The company aims to penetrate new geographic markets, with a focus on expanding its presence in Europe and North America by the end of 2025.

## Funding rounds

- Series B, Feb 14, 2019, $5.2M — Korea Investment & Securities, Widwin Investment
- Series A, Jan 15, 2016, $2.9M — Korea Investment Partners, Hanwha Investment & Securities

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- Hanwha Investment & Securities (https://capitalatlas.ai/funds/hanwha-investment-securities) — Series A
- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series B
- Widwin Investment (https://capitalatlas.ai/funds/widwin-investment) — Series B